NCT02775500
Apremilast Pregnancy Exposure Registry
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 31, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 6 versions: 4 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Study completion pushed from Jul 2025 to May 2027
- Notable Primary completion date changed from estimate of Apr 2024 to Dec 2024v6
Notable Primary completion date: Feb 2022 to Apr 2024v5 Show 4 more changesShow less
- Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 300 to confirmed 233
- Study completion date: Jul 2024 to Jul 2025
- Site details revised
- Notable Primary completion date: Feb 2021 to Feb 2022
- Study completion date: Jul 2021 to Jul 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (8)
Show 3 moreShow less
Arms and interventions
Women who have been exposed to apremilast in pregnancy for an approved indication in the first trimester of pregnancy for any length of time from the date of conception.
Women with an approved disease who have not been exposed to apremilast at any time in pregnancy.
Healthy women who have no diagnosis of an approved indication or other chronic illness, have not taken apremilast in pregnancy, nor have they been exposed to any known human teratogen during pregnancy.
Women who have been exposed to apremilast in pregnancy, for any length of time following the first day of the last menstrual period until the end of pregnancy who do not qualify for the prospective cohort study.
Drugs: apremilast
Sites
1 site in 1 country
- University of California, San DiegoLa Jolla, California, United States